TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2020.
Locate Jan Aushadhi KendraClinical Overview
Desmopressin Tablets (0.1mg) is a synthetic structural analogue of the endogenous neurohypophyseal antidiuretic hormone (8-arginine vasopressin) on the WHO Model List of Essential Medicines. Deamination of 1-cysteine and substitution with D-arginine enhances selective antidiuretic V2 receptor agonism by ~300-fold in renal collecting ducts while eliminating vasopressor V1a arterial constriction. Stimulates aquaporin-2 water channel insertion, dramatically increasing water reabsorption and reducing nocturnal urine production. Indicated for primary nocturnal enuresis (bedwetting) in children >=5 years, central diabetes insipidus, and nocturnal polyuria in adults.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Primary nocturnal enuresis: Take 0.1 mg to 0.2 mg orally at bedtime with a minimal sip of water. CRITICAL: Strictly restrict fluid intake from 1 hour before bedtime until 8 hours the following morning. Central diabetes insipidus: 0.1 mg three times daily with water, titrated based on urine volume and osmolality.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, nausea, mild abdominal pain. Rare/Severe: Severe dilutional hyponatremia, water intoxication, cerebral edema, seizures, and coma if fluid restriction is ignored.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Severe, potentially fatal hyponatremic seizures; fluid restriction is mandatory during nighttime enuresis therapy. Check baseline serum sodium and monitor periodically, especially in elderly patients. Contraindicated in polydipsia, hyponatremia, heart failure, and moderate-to-severe renal impairment (CrCl < 50 mL/min).
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.